Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer

TAS-106, a RNA polymerase inhibitor, was studied in solid tumors with potential clinical benefit and reasonable tolerability. We conducted a multicenter, international phase II trial of TAS-106 in salvage metastatic or recurrent head and neck squamous cell cancer (HNSCC) and nasopharyngeal cancer (N...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsao, Anne, Hui, Edwin Pun, Juergens, Rosalyn, Marur, Shanthi, Huat, Tan Eng, Cher, Goh Boon, Hong, Ruey-Long, Hong, Waun Ki, Chan, Anthony Tak-Cheung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699847/
https://www.ncbi.nlm.nih.gov/pubmed/23930212
http://dx.doi.org/10.1002/cam4.79

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699847/
https://www.ncbi.nlm.nih.gov/pubmed/23930212
http://dx.doi.org/10.1002/cam4.79

Ejemplares similares